We use cookies for a better user experience. Read our Privacy Policy

I Agree

Pharmacovigilance Market

Pharmacovigilance Market (Drug Development: Preclinical Studies, Phase I, Phase II, Phase III, and Phase IV or Post Marketing Surveillance; Type of Method and Type of Service) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Pharmacovigilance Market Outlook 2028

  • The global pharmacovigilance market was valued at US$ 6.1 Bn in 2020
  • It is estimated to expand at a CAGR of 8.8% from 2021 to 2028
  • The global pharmacovigilance market is expected to reach the value of US$ 11.5 Bn by the end of 2028

Analysts’ Viewpoint on Pharmacovigilance Market Scenario

The global pharmacovigilance market is growing cumulatively, as it is driven by increase in awareness within the public health sector coupled with rise in preference for safe medicines. This service is helping in surveillance of expected or unexpected effects that may appear or may be aggravated due to potential combination of drugs amid the ongoing COVID-19 pandemic. As such, the pharmacovigilance market is anticipated to thrive at a significant CAGR during the years 2021 to 2028. Globally, the growing number of national pharmacovigilance centers is playing an imperative role to support the growth of the market over the next few years. Needless to mention, pharmacovigilance is witnessing numerous challenges to develop a better healthcare system. The unavailability of skilled labor and information about drugs obtained via the web could be two high-impact restraints of the market. However, rigorous pharmacovigilance activities that could be made compulsory are expected to fuel the demand for services in the market. Such mandatory activities help to actively manage high-risk medicines.

Advanced Clinical Trial Phases Fuelling Demand for Pharmacovigilance

Stakeholders in the pharmacovigilance market are extending their services in preclinical studies, clinical trial phases I, II, III, and IV by phase of drug development. Phase IV a.k.a. post-marketing surveillance has contributed to a large share in terms of revenue in the previous years. Safety worries relating to marketed products, growing necessity of designing systems to compare safety profiles of homologous medicinal products, and rising public health awareness campaigns are few of the reasons contributing to the growth of the pharmacovigilance market.

Clinical trial phase III is predicted to set to rise at a high growth rate due to the escalating need for monitoring of drug safety. This phase emphasizes on drug safety and efficiency in diverse sub-groups, where the benefit-risk ratio is developed, scrutinized, and updated accordingly. In order to be more accurate on the part of drug safety, biopharmaceutical companies are focusing on creating advanced clinical trial phases.

To know the scope of our report Get a Sample on Pharmacovigilance Market

Pharmacovigilance Offers Health Transparency for COVID-19 Vaccines and Patient Monitoring

The need of pharmacovigilance services has increased due to the COVID-19 pandemic. Companies in the market for pharmacovigilance are taking advantage of this opportunity by increasing awareness about Coronavirus vaccine safety guidance. Information on each of the authorized vaccines, including authorization, manufacturing, and dosage, among other details, are fuelling the demand for pharmacovigilance services. This information is being presented in layers, which allow sequential access to degrees of increasing depth of information. At the same time, pharmacovigilance monitoring of COVID-19 patients has become an international priority. Healthcare organizations are encouraging this activity in an attempt to guarantee health transparency.

Get a glimpse of the in-depth analysis through our Report Brochure

Contract Outsourcing and Spontaneous Reporting Providing Impetus to Market Growth

The pharmacovigilance market is anticipated to grow at a promising rate due to the increasing demand for contract outsourcing and in-house pharmacovigilance. An important factor helping with the growth of contract outsourcing could be shift in focus to core business activities from that of non-core by outsourcing pharmacovigilance services. This will lead to a decrease in operational and financial costs suffered from delays in product approval.

The global pharmacovigilance market is positioned for a healthy growth rate throughout the assessment period. Intensified ADR (Adverse Drug Reaction) reporting, targeted spontaneous reporting, and cohort event monitoring activities are providing impetus to market growth. During the recent years, in terms of revenue, the use of spontaneous reporting method is growing at a rapid pace since it is a more accurate technique of discovering new ADRs.

Expanding operations in future? To get the perfect launch ask for a custom report

North America and Asia Pacific Hold Lucrative Revenue Opportunities for Stakeholders

Asia Pacific is expected to gain high growth during the forecast period. Factors supporting market growth in this region are envisaged to include high demand for strict healthcare regulations and increase in number of clinical trials being set up. Nevertheless, developed regions are projected to significantly contribute to the pharmacovigilance market. For instance, North America’s cost benefit gained by switching to contract research organization (CRO) outsourcing from expensive in-house activities is projected to help the region to collect a larger revenue share of the market.

Increased death rates due to adverse drug reactions and rise in patient fears regarding safety of medicinal products has propelled the North America pharmacovigilance market in the recent years. A report by Centers for Disease Control and Prevention (CDC) states that there are around several thousand deaths caused by ADRs in the U.S., which are counted among the top 10 leading causes of death in the country.

Pharmacovigilance Market: Overview

  • According to Transparency Market Research’s latest report on the global pharmacovigilance market for the historical period 2017–2019 and forecast period 2021–2028, technological advancements, adoption of artificial intelligence, and automation are projected to drive the global pharmacovigilance market during the forecast period

Technological Advancements to Drive Global Pharmacovigilance Market

  • Automation and artificial intelligence in pharmacovigilance is a boom to the pharmaceutical industry. Amid the COVID-19 pandemic, technological advancements in pharmacovigilance have come to the rescue of the chaos about the continuous clinical testing and delay in the vaccine regulatory approval. Development of centralized, web-based, and automated web portal for presenting the evaluation of the clinical trial studies related to the efficacy of the medicines used in managing the COVID-19 diseases has enlightened the physicians to improve the patient’s condition in the pandemic.
  • Usage of machine learning and advanced data analytics have created a paradigm shift in the development of drugs, assessment of drug risk profile, overview of patients safety, and optimal patient treatment
  • Automation, artificial intelligence, and analytics have driven the efficiency of the companies in providing pharmacovigilance services. Technically advanced automation, machine learning, and artificial intelligence are likely to create a paradigm shift in pharmacovigilance in the near future

Rise in Cases of Adverse Drug Reactions and Drug Toxicity

  • Surge in incidence of adverse drug reactions globally due to the high rate of drug consumption among the population is expected to propel the global pharmacovigilance market
  • Lack of well-documented post marketing adverse drug reaction reporting is projected to restrain the global pharmacovigilance market. Hence, under-reporting of adverse drug reactions would result in increase in drug toxicity incidences, which, in turn, is likely to augment the global pharmacovigilance market.
  • Increase in adverse drug reactions has compelled the regulatory authorities to adopt more stringent steps pertaining to pharmacovigilance. In August 2020, according to research studies, the average occurrence of incidence of adverse drug reactions among hospitalized pediatric patients was reported to be 9.52%.

High Risk Associated with Data Security in Pharmacovigilance Outsourcing to Hamper Market

  • Organizations are becoming increasingly connected through new platforms such as cloud and social media. Hence, there has been a consequent rise in potential threats to data security, complexity of attacks, and intensity of breaches. It is imperative for the healthcare industry to protect the proprietary and confidential information related to services and products, as there is high risk of their confidentiality being compromised.
  • Healthcare and pharmaceutical companies prefer to partner with CROs that can provide and support a high level of data security services. The contract research organization needs to assure the pharmaceutical companies that their platforms are secure, in adherence to the prescribed industry standards, and in compliance with the regulatory guidelines on data protection.
  • Despite the growing pharmacovigilance outsourcing process, pharmaceutical companies still find considering service providers reliable a major challenge, as several instances of data security breaches have been reported in the past, including illegal access to personal data through the Internet

Pharmacovigilance Market: Competition Landscape

  • This report profiles major players in the global pharmacovigilance market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global pharmacovigilance market is highly established with the presence of a number of international as well as regional players
  • Leading players operating in the global pharmacovigilance market are
    • Accenture plc
    • Bristol-Myers Squibb
    • Clinquest Group B.V.
    • Cognizant
    • Labcorp Drug Development
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • ICON plc
    • iGATE Corporation
    • iMEDGlobal Corporation
    • Syneos Health
    • Novartis AG
    • PAREXEL International Corporation
    • Pfizer, Inc.
    • Pharmaceutical Product Development, LLC. (PPD)
    • IQVIA
    • Sanofi
    • Synowledge LLC
    • Wipro Limited

Pharmacovigilance Market: Key Developments

  • Key players in the global pharmacovigilance market are engaged in technological advancements such as Big Data analytics, cloud-based database, and automation. These strategies are likely to fuel the growth of the global pharmacovigilance market. A few expansion strategies adopted by players operating in the global pharmacovigilance market are:
    • In May 2021, Cognizant reported that its pharmacovigilance services were rated best in the industry. The company offers advanced pharmacovigilance services, which ensures safety of the patients and lowers the drug adverse events.
    • In 2020, the U.K. Government entered into deal with Genpact, a U.S.-based company, for EUR 1.5 Mn to develop artificial intelligence tool for screening adverse drug reaction (ADR) reports for vaccine
    • In October 2021, Syneos Health acquired RxDataScience, a data analytics and artificial intelligence company. This will strengthen the company's large data sets for decentralized trials and the patient journey.
  • The report on the global pharmacovigilance market discussed individual strategies, followed by company profiles of pharmacovigilance services. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global pharmacovigilance market.

Pharmacovigilance Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 6.1 Bn

Market Forecast Value in 2028

US$ 11.5 Bn

Growth Rate (CAGR)

8.8% (Year-on-Year)

Forecast Period

2021–2028

Quantitative Units

US$ Bn for Value

Market Analysis

It includes cross-segment and regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • By Drug Development
    • Preclinical Studies
    • Phase I
    • Phase II
    • Phase III
    • Phase IV or Post Marketing Surveillance
  • Type of Methods
    • Spontaneous Reporting
    • Intensified ADR Reporting
    • Targeted Spontaneous Reporting
    • Cohort Event Monitoring
    • EHR Mining
  • Type of Service
    • In-house
    • Contract Outsourcing

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Japan
  • China
  • India
  • Australia & NewZealand
  • Rest of Asia Pacific
  • Brazil
  • Mexico
  • Rest of Latin America
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Companies Profiled

  • Accenture plc
  • Bristol-Myers Squibb
  • Clinquest Group B.V.
  • Cognizant
  • Labcorp Drug Development
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • ICON plc
  • iGATE Corporation
  • iMEDGlobal Corporation
  • Syneos Health
  • Novartis AG
  • PAREXEL International Corporation
  • Pfizer, Inc.
  • Pharmaceutical Phase of Drug Development, LLC. (PPD)
  • IQVIA
  • Sanofi
  • Synowledge LLC
  • Wipro Limited

Customization Scope

Available upon request

Pricing

Available upon request

Pharmacovigilance Market – Segmentation

Drug Development
  • Preclinical Studies
  • Phase I
  • Phase II
  • Phase III
  • Phase IV or Post Marketing Surveillance
Type of Methods
  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining
Type of Service
  • In-house
  • Contract Outsourcing
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Pharmacovigilance Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of pharmacovigilance market?

The global pharmacovigilance market was worth US$ 6.1 Bn and is projected to reach a value of US$ 11.5 Bn by the end of 2028

What is the anticipated CAGR of the pharmacovigilance market in the forecast period?

Pharmacovigilance market is anticipated to grow at a CAGR of 8.8% during the forecast period

Which region is expected to project the highest market share in the global pharmacovigilance market?

North America accounted for a major share of the global pharmacovigilance market

What are the key driving factors for the growth of the pharmacovigilance market?

Pharmacovigilance market is growing cumulatively, as it is driven by increase in awareness within the public health sector coupled with rise in preference for safe medicines

Who are the key players in the global pharmacovigilance market?

Key players in the global pharmacovigilance market include Accenture plc, Bristol-Myers Squibb, Clinquest Group B.V., Cognizant, Labcorp Drug Development, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, ICON plc, iGATE Corporation, iMEDGlobal Corporation, Syneos Health, Novartis AG, PAREXEL International Corporation, Pfizer, Inc., Pharmaceutical Product Development, LLC. (PPD), IQVIA, Sanofi, Synowledge LLC, and Wipro Limited

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Pharmacovigilance Market

4. Market Overview

    4.1. Introduction

        4.1.1. Market Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Pharmacovigilance Market Analysis and Forecast, 2017–2028

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. COVID-19 Impact on the Pharmacovigilance Market

    5.2. Technological Advancements (big data analytics, cloud-based database, automation)

    5.3. Drugs Regulatory Framework of Pharmacovigilance Market

    5.4. Pharmacovigilance Market: Value Chain Analysis

    5.5. Pharmacovigilance Market: Porter’s Five Forces Analysis

    5.6. Overview of Drugs Adverse Effects

6. Global Pharmacovigilance Market Analysis and Forecast, by Phase of Drug Development

    6.1. Introduction & Definition

        6.1.1. Key Findings / Developments

    6.2. Global Pharmacovigilance Market Value Forecast, by Phase of Drug Development, 2017–2028

        6.2.1. Preclinical Studies

        6.2.2. Phase I

        6.2.3. Phase II

        6.2.4. Phase III

        6.2.5. Phase IV or Post Marketing Surveillance

    6.3. Global Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028

7. Global Pharmacovigilance Market Analysis and Forecast, by Type of Method

    7.1. Introduction & Definition

        7.1.1. Key Findings / Developments

    7.2. Global Pharmacovigilance Market Value Forecast, by Type of Method, 2017–2027

        7.2.1. Spontaneous Reporting

        7.2.2. Intensified ADR Reporting

        7.2.3. Targeted Spontaneous Reporting

        7.2.4. Cohort Event Monitoring

        7.2.5. EHR Mining

    7.3. Global Pharmacovigilance Market Attractiveness Analysis, by Type of Method,2021-2028

8. Global Pharmacovigilance Market Analysis and Forecast, by Type of Service

    8.1. Introduction & Definition

        8.1.1. Key Findings / Developments

    8.2. Global Pharmacovigilance Market Value Forecast, by Type of Service, 2017–2027

        8.2.1. In-house

        8.2.2. Contract Outsourcing

    8.3. Global Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028

9. Global Pharmacovigilance Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Global Pharmacovigilance Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. North America Pharmacovigilance Market Attractiveness Analysis, by Region, 2021-2028

10. North America Pharmacovigilance Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027

        10.2.1. Preclinical Studies

        10.2.2. Phase I

        10.2.3. Phase II

        10.2.4. Phase III

        10.2.5. Phase IV or Post Marketing Surveillance

    10.3. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027

        10.3.1. Spontaneous Reporting

        10.3.2. Intensified ADR Reporting

        10.3.3. Targeted Spontaneous Reporting

        10.3.4. Cohort Event Monitoring

        10.3.5. EHR Mining Others

    10.4. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027

        10.4.1. In-house

        10.4.2. Contract Outsourcing

    10.5. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Country, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Pharmacovigilance Market Attractiveness Analysis, 2021-2028

        10.6.1. By Phase of Drug Development

        10.6.2. By Type of Method

        10.6.3. By Type of Service

        10.6.4. By Country

11. Europe Pharmacovigilance Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027

        11.2.1. Preclinical Studies

        11.2.2. Phase I

        11.2.3. Phase II

        11.2.4. Phase III

        11.2.5. Phase IV or Post Marketing Surveillance

    11.3. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027

        11.3.1. Spontaneous Reporting

        11.3.2. Intensified ADR Reporting

        11.3.3. Targeted Spontaneous Reporting

        11.3.4. Cohort Event Monitoring

        11.3.5. EHR Mining

    11.4. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027

        11.4.1. In-house

        11.4.2. Contract Outsourcing

    11.5. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Europe Pharmacovigilance Market Attractiveness Analysis, 2021-2028

        11.6.1. By Phase of Drug Development

        11.6.2. By Type of Method

        11.6.3. By Type of Service

        11.6.4. By Country/Sub-region

12. Asia Pacific Pharmacovigilance Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027

        12.2.1. Preclinical Studies

        12.2.2. Phase I

        12.2.3. Phase II

        12.2.4. Phase III

        12.2.5. Phase IV or Post Marketing Surveillance

    12.3. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027

        12.3.1. Spontaneous Reporting

        12.3.2. Intensified ADR Reporting

        12.3.3. Targeted Spontaneous Reporting

        12.3.4. Cohort Event Monitoring

        12.3.5. EHR Mining

    12.4. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027

        12.4.1. In-house

        12.4.2. Contract Outsourcing

    12.5. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Pharmacovigilance Market Attractiveness Analysis, 2021-2028

        12.6.1. By Phase of Drug Development

        12.6.2. By Type of Method

        12.6.3. By Type of Service

        12.6.4. By Country/Sub-region

13. Latin America Pharmacovigilance Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027

        13.2.1. Preclinical Studies

        13.2.2. Phase I

        13.2.3. Phase II

        13.2.4. Phase III

        13.2.5. Phase IV or Post Marketing Surveillance

    13.3. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027

        13.3.1. Spontaneous Reporting

        13.3.2. Intensified ADR Reporting

        13.3.3. Targeted Spontaneous Reporting

        13.3.4. Cohort Event Monitoring

        13.3.5. EHR Mining

    13.4. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027

        13.4.1. In-house

        13.4.2. Contract Outsourcing

    13.5. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America Pharmacovigilance Market Attractiveness Analysis, 2021-2028

        13.6.1. By Phase of Drug Development

        13.6.2. By Type of Method

        13.6.3. By Type of Service

        13.6.4. By Country/Sub-region

14. Middle East & Africa Pharmacovigilance Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027

        14.2.1. Preclinical Studies

        14.2.2. Phase I

        14.2.3. Phase II

        14.2.4. Phase III

        14.2.5. Phase IV or Post Marketing Surveillance

    14.3. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027

        14.3.1. Spontaneous Reporting

        14.3.2. Intensified ADR Reporting

        14.3.3. Targeted Spontaneous Reporting

        14.3.4. Cohort Event Monitoring

        14.3.5. EHR Mining

    14.4. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027

        14.4.1. In-house

        14.4.2. Contract Outsourcing

    14.5. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, 2021-2028

        14.6.1. By Phase of Drug Development

        14.6.2. By Type of Method

        14.6.3. By Type of Service

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share / Position Analysis, by Company, 2020

    15.3. Competitive Business Strategies

    15.4. Company Profiles

        15.4.1. Accenture plc

            15.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.1.2. Phase of Drug Development Portfolio

            15.4.1.3. Financial Overview

            15.4.1.4. Strategic Overview

            15.4.1.5. SWOT Analysis

        15.4.2. Bristol-Myers Squibb

            15.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.2.2. Phase of Drug Development Portfolio

            15.4.2.3. Financial Overview

            15.4.2.4. Strategic Overview

            15.4.2.5. SWOT Analysis

        15.4.3. Clinquest Group B.V.

            15.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.3.2. Phase of Drug Development Portfolio

            15.4.3.3. Financial Overview

            15.4.3.4. Strategic Overview

            15.4.3.5. SWOT Analysis

        15.4.4. Cognizant

            15.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.4.2. Phase of Drug Development Portfolio

            15.4.4.3. Financial Overview

            15.4.4.4. Strategic Overview

            15.4.4.5. SWOT Analysis

        15.4.5. Labcorp Drug Development

            15.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.5.2. Phase of Drug Development Portfolio

            15.4.5.3. Financial Overview

            15.4.5.4. Strategic Overview

            15.4.5.5. SWOT Analysis

        15.4.6. F. Hoffmann-La Roche Ltd.

            15.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.6.2. Phase of Drug Development Portfolio

            15.4.6.3. Financial Overview

            15.4.6.4. Strategic Overview

            15.4.6.5. SWOT Analysis

        15.4.7. GlaxoSmithKline plc

            15.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.7.2. Phase of Drug Development Portfolio

            15.4.7.3. Financial Overview

            15.4.7.4. Strategic Overview

            15.4.7.5. SWOT Analysis

        15.4.8. ICON plc

            15.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.8.2. Phase of Drug Development Portfolio

            15.4.8.3. Financial Overview

            15.4.8.4. Strategic Overview

            15.4.8.5. SWOT Analysis

        15.4.9. iGATE Corporation

            15.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.9.2. Phase of Drug Development Portfolio

            15.4.9.3. Financial Overview

            15.4.9.4. Strategic Overview

            15.4.9.5. SWOT Analysis

        15.4.10. iMEDGlobal Corporation

            15.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.10.2. Phase of Drug Development Portfolio

            15.4.10.3. Strategic Overview

            15.4.10.4. SWOT Analysis

        15.4.11. Syneos Health

            15.4.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.11.2. Phase of Drug Development Portfolio

            15.4.11.3. Financial Overview

            15.4.11.4. Strategic Overview

            15.4.11.5. SWOT Analysis

        15.4.12. Novartis AG

            15.4.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.12.2. Phase of Drug Development Portfolio

            15.4.12.3. Financial Overview

            15.4.12.4. Strategic Overview

            15.4.12.5. SWOT Analysis

        15.4.13. PAREXEL International Corporation

            15.4.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.13.2. Phase of Drug Development Portfolio

            15.4.13.3. Financial Overview

            15.4.13.4. Strategic Overview

            15.4.13.5. SWOT Analysis

        15.4.14. Pfizer, Inc.

            15.4.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.14.2. Phase of Drug Development Portfolio

            15.4.14.3. Financial Overview

            15.4.14.4. Strategic Overview

            15.4.14.5. SWOT Analysis

        15.4.15. Pharmaceutical Phase of Drug Development, LLC. (PPD)

            15.4.15.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.15.2. Phase of Drug Development Portfolio

            15.4.15.3. Financial Overview

            15.4.15.4. Strategic Overview

            15.4.15.5. SWOT Analysis

        15.4.16. IQVIA

            15.4.16.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.16.2. Phase of Drug Development Portfolio

            15.4.16.3. Financial Overview

            15.4.16.4. Strategic Overview

            15.4.16.5. SWOT Analysis

        15.4.17. Sanofi

            15.4.17.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.17.2. Phase of Drug Development Portfolio

            15.4.17.3. Financial Overview

            15.4.17.4. Strategic Overview

            15.4.17.5. SWOT Analysis

        15.4.18. Synowledge LLC

            15.4.18.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.18.2. Phase of Drug Development Portfolio

            15.4.18.3. Strategic Overview

            15.4.18.4. SWOT Analysis

        15.4.19. Wipro Limited

            15.4.19.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.19.2. Phase of Drug Development Portfolio

            15.4.19.3. Financial Overview

            15.4.19.4. Strategic Overview

            15.4.19.5. SWOT Analysis

List of Tables

Table 01: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028

Table 02: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028

Table 03: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028

Table 04: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Region, 2017–2028

Table 05: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028

Table 06: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028

Table 07: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028

Table 08: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Country, 2017–2028

Table 09: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028

Table 10: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028

Table 11: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028

Table 12: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

Table 13: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028

Table 14: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028

Table 15: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028

Table 16: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

Table 17: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028

Table 18: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028

Table 19: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028

Table 20: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

Table 21: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028

Table 22: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028

Table 23: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028

Table 24: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

List of Figures

Figure 01: Pharmacovigilance Market Snapshot

Figure 02: Global Pharmacovigilance Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2027

Figure 03: Market Value Share, by Phase of Drug Development, 2018

Figure 04: Market Value Share, by Type of Service, 2018

Figure 05: Market Value Share, by Region, 2018

Figure 06: Global Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028

Figure 07: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Preclinical Studies, 2017–2028

Figure 08: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase I, 2017–2028

Figure 09: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase II, 2017–2028

Figure 10: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase III, 2017–2028

Figure 11: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase IV or Post Marketing Surveillance, 2017–2028

Figure 12: Global Pharmacovigilance Market Attractiveness Analysis, 2021-2028, by Phase of Drug Development

Figure 13: Global Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028

Figure 14: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), Spontaneous Reporting, 2017–2028

Figure 15: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Intensified ADR Reporting, 2017–2028

Figure 16: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Targeted Spontaneous Reporting, 2017–2028

Figure 17: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cohort Event Monitoring, 2017–2028

Figure 18: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by EHR Mining, 2017–2028

Figure 19: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2028

Figure 20: Global Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028

Figure 21: Global Pharmacovigilance Market Value Share Analysis, by Type of Service Providers, 2020 and 2028

Figure 22: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by In-house, 2017–2028

Figure 23: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Outsourcing, 2017–2028

Figure 24: Global Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028

Figure 25: Global Pharmacovigilance Market Value Share Analysis, by Region, 2020 and 2028

Figure 26: Global Pharmacovigilance Market Attractiveness Analysis, by Region, 2021-2028

Figure 27: North America Pharmacovigilance Market Size (US$ Mn) Forecast, 2017–2028

Figure 28: North America Pharmacovigilance Market Attractiveness Analysis, by Country, 2021-2028

Figure 29: North America Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028

Figure 30: North America Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028

Figure 31: North America Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028

Figure 32: North America Pharmacovigilance Market Value Share Analysis, by Country, 2020 and 2028

Figure 33: North America Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028

Figure 34: North America Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028

Figure 35: North America Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028

Figure 36: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, 2017–2028

Figure 37: Europe Pharmacovigilance Market Attractiveness Analysis, by Country, 2021-2028

Figure 38: Europe Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028

Figure 39: Europe Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028

Figure 40: Europe Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028

Figure 41: Europe Pharmacovigilance Market Value Share Analysis, by Country, 2020 and 2028

Figure 42: Europe Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028

Figure 43: Europe Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028

Figure 44: Europe Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028

Figure 45: Asia Pacific Pharmacovigilance Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017– 2028

Figure 46: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Country 2021–2028

Figure 47: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028

Figure 48: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028

Figure 49: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028

Figure 50: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Country, 2018 and 2027

Figure 51: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028

Figure 52: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028

Figure 53: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028

Figure 54: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2028

Figure 55: Latin America Pharmacovigilance Market Attractiveness Analysis, 2021-2028, by Country/Sub-region, 2021–2028

Figure 56: Latin America Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028

Figure 57: Latin America Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028

Figure 58: Latin America Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028

Figure 59: Latin America Pharmacovigilance Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 60: Latin America Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028

Figure 61: Latin America Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028

Figure 62: Latin America Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028

Figure 63: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, 2017–2028

Figure 64: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Country/Sub-region, 2021-2028

Figure 65: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028

Figure 66: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028

Figure 67: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028

Figure 68: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 69: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028

Figure 70: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028

Figure 71: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028

Figure 72: Global Pharmacovigilance Market Share Analysis, by Company (2020)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

848

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved